publications

PUBLICATIONS AND
PRESENTATIONS

Filter by

All Molecules

All Molecules

Etrumadenant (AB928)

AB680

Domvanalimab (AB154)

Zimberelimab (AB122)

Discovery Pipeline

All Conferences

All Conferences

AACR

ASCO

ENA

ESMO

Keystone

SITC

Manuscripts

Date
Conference

November 9, 2020

Society for Immunotherapy of Cancer (SITC)

October 24-25, 2020

32nd EORTC-NCI-AACR (ENA) Symposium

October 24-25, 2020

32nd EORTC-NCI-AACR (ENA) Symposium

June 22-24, 2020

Annual Meeting of the American Association of Cancer Research (AACR)

Audio: Efficacy and safety of etrumadenant plus modified FOLFOX-6 in participants with metastatic colorectal cancer: initial results at the recommended dose for expansion (ARC-3).

M Cecchini, et al.

January 19-24, 2020

Keystone Symposia Conference

November 6-10, 2019

Society for Immunotherapy of Cancer (SITC)

November 6-10, 2019

Society for Immunotherapy of Cancer (SITC)

October 26-30, 2019

AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics

July 23, 2019

Biochemistry

March 29 – April 3, 2019

Annual Meeting of the American Association of Cancer Research (AACR)

March 29 – April 3, 2019

Annual Meeting of the American Association of Cancer Research (AACR)

March 29 – April 3, 2019

Annual Meeting of the American Association of Cancer Research (AACR)

March 29 – April 3, 2019

Annual Meeting of the American Association of Cancer Research (AACR)

March 29 – April 3, 2019

Annual Meeting of the American Association of Cancer Research (AACR)

March 29 – April 3, 2019

Annual Meeting of the American Association of Cancer Research (AACR)

March 29 – April 3, 2019

Annual Meeting of the American Association of Cancer Research (AACR)

March 10-14, 2019

Keystone Symposia Conference C2

November 7-11, 2018

Society for Immunotherapy of Cancer (SITC)

Combining To CureTM

These molecules and their uses are investigational, have not been proven to be safe, and have not been approved by the U.S. Food and Drug Administration.